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Abstract
Background: Hypertrophic Cardiomyopathy (HCM) is a complex myocardial disorder with a recognized genetic
heterogeneity. The elevated number of genes and mutations involved in HCM limits a gene-based diagnosis that
should be considered of most importance for basic research and clinical medicine.
Methodology: In this report, we evaluated High Resolution Melting (HRM) robustness, regarding HCM genetic
testing, by means of analyzing 28 HCM-associated genes, including the most frequent 4 HCM-associated sarcomere
genes, as well as 24 genes with lower reported HCM-phenotype association. We analyzed 80 Portuguese
individuals with clinical phenotype of HCM allowing simultaneously a better characterization of this disease in the
Portuguese population.
Results: HRM technology allowed us to identify 60 mutated alleles in 72 HCM patients: 49 missense mutations, 3
nonsense mutations, one 1-bp deletion, one 5-bp deletion, one in frame 3-bp deletion, one insertion/deletion, 3
splice mutations, one 5’UTR mutation in MYH7, MYBPC3, TNNT2, TNNI3, CSRP3, MYH6 and MYL2 genes. Significantly
22 are novel gene mutations.
Conclusions: HRM was proven to be a technique with high sensitivity and a low false positive ratio allowing a
rapid, innovative and low cost genotyping of HCM. In a short return, HRM as a gene scanning technique could be
a cost-effective gene-based diagnosis for an accurate HCM genetic diagnosis and hopefully providing new insights
into genotype/phenotype correlations.
Keywords: Hypertrophic cardiomyopathy, Gene-based diagnosis, High Resolution Melting, Sarcomere proteins,
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Background
Hypertrophic cardiomyopathy (HCM) is the most com-
mon monogenic disease of the cardiovascular trait
affecting 1:500 individuals in the general population
[1-3]. HCM is classically characterized by unexplained
left ventricular hypertrophy (LVH) and distinct histo-
pathological features comprising myocyte disarray and
interstitial fibrosis [1-3]. Clinical evaluation may be
triggered in response to symptoms, in asymptomatic
individuals in the course of a family screening, or after
detection of a systolic murmur or an abnormal electro-
cardiogram (ECG). HCM diagnosis is typically per-
formed by the identification of unexplained LVH on
cardiac imaging studies. Nevertheless, the morphologic
pattern of LVH is not closely predictive of the severity
of symptoms or prognosis [1]. HCM is a complex and
heterogeneous disease with remarkable diversity in the
course of disease, age of onset, symptoms severity, left
ventricular outflow obstruction, and risk for sudden car-
diac death (SCD) [1]. Indeed, some individuals experi-
ence no or only minor symptoms, while others may
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(HF) requiring cardiac transplantation. The most and
serious consequences of HCM are though, HF and SCD
[1,2,4,5]. HCM is also the leading cause of SCD in com-
petitive athletes in whom it may be the only clinical
manifestation of the disease [6].
Genetic studies established the paradigm that HCM is
a disease of the sarcomere. With a dominant transmis-
sion pattern, HCM is caused by over 1000 distinct
mutations identified in over 29 genes including those
encoding sarcomeric proteins (Table 1) [1]. This fact
underlines that behind the clinical heterogeneity seen in
HCM there is also substantial genetic heterogeneity, at
both allelic and non-allelic levels. With a higher preva-
lence when family history of HCM is present, mutations
in the genes encoding cardiac b-myosin heavy chain
(MYH7), cardiac myosin binding protein C (MYBPC3),
cardiac troponin T (TNNT2), and cardiac troponin I
(TNNI3) are the most prevalent and all together account
for over 80%-90% of HCM cases [1,7,8].
Although rare, mutations in other sarcomere- asso-
ciated genes, particularly in Z-band proteins coding
genes such as telethonin (TCAP)a n dm u s c l eL I Mp r o -
tein (CSRP3), have been described in HCM (Table 1)
[9]. The Z band is critical for cyto-architecture and is
involved in mechanosensory signalling of
Table 1 Proteins/genes associated with HCM
Protein Gene OMIM ID Reference sequence
(a) Mutations Known
(b)/prevalence
(c)
Sarcomeric Proteins
Cardiac myosin-binding protein C
(d) MYBPC3 600958 NM_000256 294/~40
b-cardiac myosin heavy chain
(d) MYH7 160760 NM_000257 335/~40
Cardiac Troponin T
(d) TNNT2 191045 NM_000364 60/~5
Cardiac Troponin I
(d) TNNI3 191044 NM_000363 50/~5
Regulatory myosin light chain MYL2 160781 NM_000432 13/~1
a-Tropomyosin
(d) TPM1 191010 NM_0001018005 24/~2
Cardiac actin ACTC1 102540 NM_005159 18/~1
Essential myosin light chain MYL3 160790 NM_000258 11/~1
Cardiac Troponin C TNNC1 191040 NM_003280 12/rare
a-myosin heavy chain MYH6 160710 NM_002471 22/rare
Titin TTN 188840 NM_133378 20/rare
Obscurin OBSCN 608616 NM_052843 1/rare
Desmin DES 125660 NM_001927 1/rare
Caveolin 3 CAV3 601253 NM_033337 1/rare
Z-band
Muscle LIM protein (MLP) CSRP3 600824 NM_003476 12/?
Telethonin TCAP 604488 NM_003673 11/?
Myozenin 2 MYOZ2 605602 NM_016599 2/?
Vinculin VCL 193065 NM_014000 1/?
Calcium-Handling HCM
Junctophilin 2 JPH2 605267 NM_020433 4/?
Phospholamban PLN 172405 NM_002887 8/?
Myosin Light Chain Kinase 2 MYLK2 606566 NM_033118 2/?
Calsequestrin 2 CASQ2 114251 NM_001232 1/?
Other non-sarcomeric proteins
Myosin VI MYO6 600970 NM_004999 1/?
Solute carrier family 25 member 4 SLC25A4 103220 NM_001151 1/?
Cytochrome C oxidase assembly protein 15 COX15 603646 NM_078476 2/?
HCM Phenocopies
2 subunit of AMP-activated protein kinase PRKAG2 602743 NM_016203 10/?
V-raf-1 murine leukemia viral oncogene homolog 1 RAF1 164760 NM_002880 1/?
Frataxin FXN 606829 NM_000144 1/?
Lysosome associated membrane 1 LAMP2 309060 NM_002294.2 1/?
These include the sarcomeric proteins, Z-band, calcium-handling, mitochondria, HCM phenocopies and other non-sarcomeric proteins whose mutations have
been associated with HCM. The OMIM, Reference sequence
(a), number of HCM-associated mutations known
(b) and prevalence of mutations
(c) are also indicated
(a) UCSC Genome Browser http://genome.ucsc.edu/cgi-bin/hgGateway;
(b) Human Genome Mutation Database http://www.hgmd.org and Harvard Sarcomere
mutation Database http://genepath.med.harvard.edu/~seidman/cg3/;
(c) [1];
(d) Clinical Genetic Test available in Portugal
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induced release and signalling and in mitochondrial
function have also been implicated in HCM (Table 1)
[1,10-12]. Phenocopies of HCM have been identified
were cardiac hypertrophy is caused by mutations in
genes distinct from those that encode sarcomere pro-
teins (Table 1) [1].
Currently, most of the mutations identified are novel
sequence variants, not previously identified as patho-
genic mutations [1,13-16]. Furthermore, when novel
sequence variants are identified, family studies to con-
firm cosegregation of the mutation are valuable. A rela-
tively high rate (3% to 10%) of compound heterozygosity
has also been observed in HCM [1,14,17,18].
Recent genetic studies demonstrate variability in the
types of HCM-mutations among different populations.
In the Netherlands or in the Southeast Asian Indian
population HCM-founding mutations are the main
cause while in the USA there is marked genetic hetero-
geneity and most HCM patients have a unique patho-
genic mutation [1,19,20]. However, HCM genetic basis
in Portugal has not yet been extensively studied [4-6,21].
Understanding the genetic basis of HCM provides an
opportunity for gene-based diagnosis with benefits for
HCM in basic research and clinical medicine, which are
currently limited by the considerable costs of genetic
testing strategies and an incomplete knowledge of all
disease genes [1,8,10,13,22].
The current “gold standard” genetic diagnosis test for
HCM in Portugal is automated dideoxi-Sequencing (AS)
of the most frequent mutated HCM-genes (Table 1-
(d)).
AS has a low throughput and high cost, and most
importantly it does not include genes coding for other
proteins related to myocardium contraction such as the
Z-band. As a consequence more than 1/3 of proband
remains to characterize as nom u t a t i o ni sf o u n d .T h i s
fact underlines the need to screen more genes using
high-throughput sensitive techniques which will enable
a more reliable genetic diagnosis [23,24] and further
hampers the cost effectiveness of the current genetic
test.
In fact, the number of HCM phenotype-associated
mutations in 29 different genes (Table 1), make full
molecular testing by AS unbearably slow and expensive,
prompting Real time PCR techniques has an alternative
technique [18,24]. High Resolution Melting (HRM) is a
high throughput gene variation scanning technique that
relies on the differential melting properties of sequences
that vary in at least one nucleotide. For this reason it is
used to identify novel mutations within samples. Unlike
other scanning methods, HRM analysis provides a
closed tube system that reduces the risk of contamina-
tion, decreases analysis time and requiring no post-PCR
sample handling. Recent results from our group [24]
and others [18] have already proved the effectiveness of
this technique for the identification of alterations in
HCM patients. Nevertheless, the cohorts of population
used in both studies were low (13 and 34 respectively)
[18,24].
T h ea i mo ft h ep r e s e n tw o r kw a st oi m p r o v eH C M
gene-based diagnosis by applying a high throughput
Real Time PCR-based technique, HRM, to study the
prevalence of HCM-mutations in a higher Portuguese
HCM cohort. The results of this work will contribute to
understand the genetic basis and variability in HCM
among our population.
Population and methods
DNA samples
Peripheral blood was collected from 80 Portuguese
unrelated patients and from 100 healthy subjects (con-
trols without any cardiovascular disease). With the
exception of control individuals, all index patients pre-
sented either familial history of HCM or clinical diagno-
sis of HCM. Diagnosis was established on clinical, ECG
and Echocardiograph (ECHO) grounds. ECG/ECHO cri-
t e r i ah a v eb e e np r e v i o u s l yd i s c u s s e da n dp u b l i s h e d[ 5 ] .
Available biometrical characteristics and clinical data are
described in Table 2. This study was approved by the
Ethics Committee of the Lisbon Faculty of Medicine
and all patients have signed an informed consent for
genetic analysis. DNA was extracted from the blood
samples using a Blood DNA kit (Roche Applied Science)
accordingly with the manufacturer procedure http://
www-roche.com.
HRM analysis
Mutation scanning of all samples was performed using a
HRM technique in a Real-Time PCR thermal cycler
(LightCycler 480, Roche Diagnostics) as described in our
previous work [24]. Primers were constructed according
to the common HRM specifications http://www.gene-
quantification.de/LC480-Technical-Note-01-HRM.pdf,
using the following onlines o f t w a r ea n dd a t a b a s e s :
UCSC Genome Browser http://genome.ucsc.edu/cgi-bin/
hgGateway, Primer 3 http://frodo.wi.mit.edu/, DINA-
Melt http://mfold.rna.albany.edu/?q=DINAMelt, Poland
service http://www.biophys.uni-duesseldorf.de/local/
POLAND/poland.html and Primer-BLAST http://www.
ncbi.nlm.nih.gov/tools/primer-blast (Additional file 1:
Table 1). Amplicon lengths were kept relatively short to
improve the detection of genetic variations. In this
regard, exons which were greater than 315 bp or exons
with more than two melting domains were amplified in
more than one overlapping segments, covering exons/
intron boundaries (Additional file 1: Table 1). The
HPLC grade primers were purchased from Metabion
(Germany). Exons 3 and 12 of the MYH7 gene, exon 30
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Page 3 of 13Table 2 Biometric and clinical data of HCM patients studied in this work
Patient
sample code
Gender: Male (M),
Female (F)
Age HCM:familial
(f), sporadic (s)
Hypertrophy: apical (a), septal (s), diffuse (d),
parietal (p), obstructive (ob)
CDI:Yes (y),
No (n)
SCD familial history:
Yes (y), No (n)
1 F 55 f d (> s), ob, deceased y y
2 M 19 s na na na
3 M1 8 f s n y
4 F6 8 sp n n
5 M 69 s p, s n n
6 M 50 s na na na
7 M 25 s d (> s), ob n n
8 M5 8 f d n n a
9 M7 2 f a n n a
10 Mn a f d ( > s ) n n
11 M3 3 f s n n
12 M 37 f na na na
13 M5 8 f a y n a
14 Mn a f s n n
15 M 58 f na n na
16 M3 8 f a y n a
17 F6 1 fa n n a
18 M 51 s s, ob n n
19 F 64 s na n na
20 F 32 s na na na
21 F 69 f na na na
22 M 55 f na na na
23 M na s na na na
24 M2 2 f s n n
25 F 25 s na na na
26 F3 1 ss n n
27 Mn a f s n n
28 F6 2 fa y n
29 M 19 s na na n
30 F5 5 fa y n a
31 M5 4 f a n n a
32 F6 1 sp n n
33 M 51 f na na na
34 M3 9 f s y n a
35 M 19 s na na na
36 M 42 s na na na
37 M2 9 ss n a n a
38 M 30 f na na na
39 M6 7 f s y y
40 M2 1 sd n n
41 F na s p, s, ob n n
42 F 70 s na na na
43 F 14 s na na na
44 M 84 f na na na
45 F 45 f na na na
46 M 42 f na na na
47 M na s na na na
48 M4 4 sp n n
49 M 47 s p, s, ob n n
50 M 50 s na y na
51 F8 2 sd ( > s ) n n
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Page 4 of 13of the MYBPC3 gene and exons 1, 2, and 3 of TNNI3
gene contain several highly prevalent polymorphisms,
nevertheless, they were also included in our study and
whenever an alteration was found in one of those geno-
mic regions by HRM, the corresponding sample was
submitted to AS. Reference sequences of the genes were
obtained from the Genome Browser of the University of
California Santa Cruz http://genome.ucsc.edu/cgi-bin/
hgGateway. LightCycler
®480 High Resolution Melting
Master kit (Roche Applied Science) which includes a
hot start PCR enzyme and the ResoLight saturating
DNA dye was used for the amplification of all the 208
genomic regions, accordingly with the manufacturer
procedure http://www.roche.com. The PCR conditions
used to amplify all amplicons are described in Addi-
tional file 1: Table 1. The amplification conditions were
composed of 35 PCR cycles of denaturation at 95°C for
10 seconds, primer annealing at an optimized tempera-
ture for 10 seconds and an extension at 72°C for 20 sec-
onds. Melting and fluorescence detection conditions
were as indicated by the supplier (Roche Diagnostics).
Briefly, immediately after amplification, the PCR pro-
ducts were heated to 95°C and cooled to 40°C (for het-
eroduplex formation), and melting was monitored (by
fluorescence emission) from 65°C to 95°C. Using the
LightCycler 480
®1.5.0.39 SP3 software (Roche Diagnos-
tics), melting data was normalized, temperature shifted
and displayed as derivative curves compared to the con-
trol samples. The auto-group function was applied to
generate automatic genotype group analyzing the melt
profiles and clustering samples into groups with similar
melting profiles. An altered sample was considered
whenever: the generated melting curve was different
from control samples; it was grouped apart from the
controls; and presented a relative signal difference out
of the range of normality limits (+2 to -2. When an
altered profile was found, the PCR product was purified
and sequenced (as a paid service, TRACEGEN).
Whenever a mutation was confirmed in a proband,
first and second degree relatives were tested, whenever
possible, for the identified variant in order to check the
co-segregation with the disease in the family. Except for
Table 2 Biometric and clinical data of HCM patients studied in this work (Continued)
52 F 64 f na na na
53 F 74 f p, s n n
54 M 59 s ob y na
55 M 53 f na na na
56 F7 0 fa n n a
57 F 61 f s, ob y y
58 M 41 f na na na
59 F 18 s na na na
60 Mn a sd n a n a
61 Mn a sa n n
62 Mn a f s n n
63 F 78 s na na na
64 M 54 s na na na
65 M 82 s p, s, ob n n
66 M na s na na na
67 M2 1 ss n a n
68 Mn a ss n n
69 F3 1 sa n n
70 F7 8 sp n n
71 M5 2 f s n n
72 F 49 f na na na
73 F7 8 fa n n a
74 M 42 s na na na
75 F 58 f na na na
76 F 80 f na na na
77 F 78 s na na na
78 F na f na na na
79 F na f d (> s), ob, deceased n n
80 M 55 f na na n
For some of the patients no information was available regarding the data analyzed (na: data not available; CDI - cardio defibrillator; SCD - sudden cardiac death)
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Page 5 of 13non sense and frame shift mutations, due to short inser-
tions or deletions and splice site mutations, a missense
variant was considered as a mutation when: - it co-seg-
regates with the disease in the family; - affects an amino
acid conserved among species and isoforms; and - it
failed to be detected in at least 200 chromosomes of
healthy adult controls (CS01-CS101).
Single-strand conformation polymorphism analysis
In order to confirm HRM reliability, mutation scanning
was also performed through Single-Strand Conformation
Polymorphism (SSCP) analysis. Selected exons and
flanking intronic regions were amplified through PCR.
Each amplicon was denatured and single strand confor-
mational profile was evaluated using GenePhor™ DNA
Electrophoresis System and PlusOne™ DNA Silver
Staining Kit (GE HealthCare Life Sciences). All ampli-
cons with different migration pattern (by comparison
with the same amplicon from a healthy control indivi-
dual) were sequenced for DNA alteration confirmation.
Results and discussion
PCR optimization
Since 2002, HRM scanning method has been applied in
human diseases genotyping and used for high through-
put mutation scanning on genes, for which large cohorts
of patients have to be investigated [18,24-29]. As
described previously by us and others [18,24], HRM
scanning accuracy depends on high quality PCR, mean-
ing that optimization a critical step and that the pre-
sence of primer dimers or non specific products may
alter the melt curve characteristics causing the genera-
tion of false positive results. HRM analysis optimization
was previously performed by us, using 3 control DNAs
(previously sequenced) and 7 DNAs carrying previously
identified HCM genetic variants (see Additional file 1:
T a b l e1 ) .U s i n gt h i ss t r a t e g yw eh a v ed e m o n s t r a t e d
HRM potential to identify mutations in genes that are
not usually analyzed in standard diagnostic techniques
such as AS [24].
Molecular analysis of 80 HCM patients
The fact that the genetic basis for HCM in Portugal has
not yet been extensively studied in large cohort of HCM
patients, and the success of HRM as a high throughput
and fast analysis technology, drove us to perform a
mutational screening of 28 HCM-associated genes using
this technology in 80 Portuguese HCM patients (not
previously studied). This cohort was also studied by
SSCP where all genetic variants detected by HRM analy-
sis were also identified. Similar results were previously
reported for other genes such as F8, NF2, CFTR,
LMNA,a n dSCN5A [25-29]. All DNA amplicons
detected as altered through HRM or SSCP were
sequenced for mutation confirmation. As HRM could
induce some false positives, each amplicon was tested
against a mean of 3 wild-type samples in order to
decrease significantly the number of false positive calls.
Molecular analysis of this cohort allowed the identifi-
cation of 96 genetic variants, of which 38 were HCM-
known mutated alleles (31 missense mutations, three
nonsense mutations, one 1-bp deletion, one in frame 3-
bp deletion, one 5-bp deletion and one splice mutation)
and 22 were novel mutations (18 missense mutations,
one indel, two splice mutations and one promoter muta-
tion) (Table 3).
The novel missense mutations affected highly con-
served amino acid residues, and were not found in 200
control chromosomes (Caucasian origin) (Figures 1, 2, 3,
4 and 4 data not shown).
Fourteen patients (17.5%) are carriers of two
mutated alleles (patients 3, 7, 10, 11, 13, 21, 27, 33,
35, 37, 39, 43, 45 and 47). Patient 12 is a carrier of
three mutated alleles and patient 22 carries three
mutated allele plus one 5’UTR mutation with
unknown effect (See Additional file 2: Figure S1 and
d a t an o ts h o w n ) .I ne i g h tp a t i e n t s( 1 0 % )n om u t a t e d
allele was found (patients 8, 19, 36, 40, 63, 64, 65 and
7 3 ) .T h i ss u g g e s t st h a to t h e rg e n e s ,n o ti n c l u d e di n
this study, or still not yet known may be responsible
for the disease in these HCM patients. Nevertheless,
compared with previous AS reported detection capa-
city (no mutation found in 1/3 of the patients) our
strategy allowed us an improved characterization of
HCM patients [23].
In patients 67, 68 and 69 we have found only a single
SNP (rs3730238/CM034583) c.779A > G (p.Lys260Arg)
in exon 14 of TNNT2 gene also described as HCM-asso-
ciated in the Human Genome Mutation Database http://
www.hgmd.org (Figure 5a, b and 5c).
Despite being described as a SNP, and Pholyphen
score classify it as benign (Figure 5d), it affects a codon
that is conserved in different species (Figure 5e). More-
over, HRM population study of exon 14 of TNNT2 gene
in 200 chromosomes from healthy control Caucasian
Portuguese individuals, allow us to find this allele
(rs3730238) in 3 chromosomes from control individuals
(1.5%) (Figure 5f and 5g). This SNP has also been found
in more European populations, namely in Spanish and
French individuals [18,30,31]. Interestingly, it has not
been described in more geographically distant popula-
tions, such as the Indian population [32]. In this regard,
since in these three HCM patients (67, 68 and 69) we
were not able to detect other mutated allele, segregation
studies within their families are being performed regard-
ing this SNP. We cannot discharge that these 3 patients
can have a mutated allele in another gene (not yet
known or not analyzed in the current study).
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Exon Mutation
(a) or SNP
(b) code or reference Genetic variation Patient sample code
MYBPC3
4 rs3729986 c.465 G > A, p.Val158Met 1
5 rs11570052 c.565 G > A, p.Val189Ile 2
6 CM043536 c.706 A > G, p.Ser236Gly 3, 4, 5
7 [24] c.817 C > T, p.Arg273Cys 6
8 New c.851 + 95 C > G 7
9 CS041890 c.852-20 C > A 2
13 Synonym c.1233 T > G, p.Phe411Phe 8
14 New c.1454 + 34 G > C 9
15 CM981324 c.1481 G > A, p.Arg494Gln 10
CM981325 c.1502 G > A, p.Arg501Gln 11, 12, 13
16 [24] c.1727 G > A; p.Trp576X 14
Synonym c.1626 G > C, p.Lys542Lys 9, 15
19 New c.1945insT1941-1946delCCTGGA, 16, 17
p.Pro647fs
18 New c.1925-24 T > C 18
21 rs3729948 c.2305 + 18 C > G 19
22 New c.2344 G > C, p.Val782Leu 20
23a New c.2470 C > A, p.Leu824Met 10
CM041808 c.2523 C > G p.Tyr841X 21
New c.2411-2 A > T 22
24 rs3729936 c.2734 + 12 C > T 19
CM992932 c.2683 G > A, p.Val895Met 23, 24
25 CM032959 c.2824 C > T, p.Arg942X 1, 25, 26
[24] c.2759A > T, pGln920Leu 11, 12
New c.2780 C > T;Ser927Leu 27
27 New c.3187 + 36 C > A 28
28 New c.3283 G > A p.Glu1095Lys 29
30 New c3581G > T, p.Gly1195Val 7
MYH7
3 Synonym c.189 C > T, p.Thr63Thr 30, 31, 32
5 CM034049 c.502 + 23 T > C 4, 5, 32, 33
c.427 C > G; p.Arg143Gly 3
7 New c.639 + 31 C > T 30, 31
Synonym c.7647 A > G, pAla199Ala 15, 16
CM031267 c.611 G > A, pArg204His 34
New c.613A > T p.Ser205Cys 30, 31
New c.625 C > G, p.Gln209Glu 80
8 Synonym c.732 C > T, pPhe244Phe 35, 36, 37
New c. 671 A > T, p.Asn224Ile 37
9 CM981329 c. 788 T > C, p. Ile263Thr 18, 27, 38
11 CM033923 C958G > A, p.Val320Met 39
Synonym c.975 C > T, pAsp325Asp 34
12 Synonym c.1095 G > A, p.Lys365Lys 3
Synonym c.1062 C > T, p.Gly354Gly 3
Synonym c. 1128 C > T, p.Asp376Asp 37, 40
13 CM930503_rs3218714 c.1208 G > T, p.Arg403Leu 12
CM032602 c.1231 G > A, p.Val411Ile 35, 41
New c.1252 C > A, p.Gln418Lys 42
14 CM003684 c.1358 G > A; p.Arg453His 43
15 New c.1408-35 T > C 44, 45, 46
New c.1486 C > T, p.Leu496Ser 47
16 CM920491(G > A) c.1750 G > C, p.Gly584Arg 33
17 Harvard c.1954ª > G, p.Arg652Gly 48
Santos et al. BMC Medical Genetics 2012, 13:17
http://www.biomedcentral.com/1471-2350/13/17
Page 7 of 13Table 3 List of genetic variations identified by HRM analysis (Continued)
19 CM054010 c.2093 T > C; p.Val698Ala 39
CM941086 c.2155 C > T, p.Arg719Trp 49
20 rs3729818 c.2163-56 A > G 8
New c.2189 T > C, p.Ile730Thr 32
CM95212 c.2221 G > T, p. Gly741Trp 50
22 CM032607 c. 2470 G > A, p.Val824Ile 21
Harvard c.2539-2541del; p. Lys847del 51, 52
New c.2585 > T, p.Ala862Val 13
CM952025 c.2609 G > A; p.Arg870His 53
CM010347 c.2630 T > A; p.Met877Lys 54
CM034055 c.2644 C > G; p.Gln882Glu 43, 45
23 CM052262 C.2702 C > G, p.Ala901Gly 55
CM042418 c.2761 G > A; p.Glu921Lys 56
CM920494 c.2770 G > A, p.Glu924Lys 57, 58
24 Synonym c.267 T > C, p.Ile989Ile 35, 40, 59
32 CM050712 c.4472 C > G, p.Ser1491Cys 60
37 CM06819 c.5305 C > A, p.Leu1769Met 47
38 New c.5573 G > T, p.Arg1858Met 59
rs3729833 c.5655 + 32 G > A 3, 35, 59, 61
TNNT2
3 New c.42-58 G > A 61
4 CD044989 c.53-11_53-7del5 (CTTCT) 12
7 rs3729843 c.164-50 G > A 62
9 Synonym c.237 G > A, p.Ser79Ser 63
10 Synonym c.348 T > C,p.Ile116Ile 64, 65
New c.406A > T, p. Arg136Trp 66
14 New c.722 A > T, p.Lys241Met 22
CM034583_rs3730238 c.779A > G, p.Lys260Arg 67, 68, 69
New c.781 + 8 G > A 33
15 New c.802-33 C > T 70
CM031384 c. 833A > T, p.Asn278Ile 71, 72
16 New C.843-35 T > C 44, 45, 46
rs3729998 c.888 + 66 G > A 73
TNNI3
1 New c.-52 A > T 22
rs3729707 c.-35 C > A 22
4 New c.150 + 27_28CG > GC 4,56, 48
7 CM031378 c.422 G > A, p.Arg141Gln 45
New c.462 G > A, p.Met155Ile 44, 46
CM031379 c.470 C > T, p. Ala157Val 74
CM973090 c.484 C > T, p.Arg162Trp 15, 75, 76
New c.521A > T, p.Lys174Met 77
MYH6
2 New c.220 G > A, p.Gly56Arg 37
MYL2
3 New c.132 T > C, p.Ile44Met 35
CSRP3
3 CD062135 c.128delC, p.Ala43Valfs165 22, 78, 79
New c.170A > C, p.Tyr57Ser 62
CM030827 c.131 T > C, p.Leu44Pro 7
Genetic variants indicated in bold correspond to mutations, others to SNPs
(a)Human Genome Mutation Database http://www.hgmd.org and Harvard Sarcomere mutation Database http://genepath.med.harvard.edu/~seidman/cg3/;
(b)http://www.ensembl.org/Homo_sapiens/Info/Index.
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Page 8 of 13In healthy patients, beside the SNP mentioned above,
only synonym changes were found (data not shown).
HRM gene scanning data for MYBPC3 and TNNT2 is
presented in Additional file 3: Figure S2 and Additional
file 4: Figure S3, respectively.
In silico characterization of novel HCM-causing mutations
The pathogenicity of novel mutations will be further
assessed using segregation analysis and two-hybrid
based protein functional assays. However, in silico stu-
dies based on the use of PolyPhen software v2.0.23
Figure 1 a) Melting curves of exon 19 of the MYBPC3 gene (NM_000256).b )D i f f e r e n c ep l o to ft h em e l t i n gc u r v e so fe x o n1 9o ft h e
MYBPC3 gene. The arrows in both figures indicate the wild-type (wt) profile and patient 16 respective variations. Two healthy control individuals
were used has a reference curve. c) Chromatogram analysis resulting from sequencing exon 19 of the MYBPC3 gene in patient 16 with the
c.1945insT, 1941-1946delCCTGGA, p.Pro647fs. This mutation was also present in patient 17. d) Melting curves of exon 22(1) of the MYH7 gene
(NM_000257). e) Difference plot of the melting curves of exon 22(1) of the MYH7 gene. The arrows in both figures indicate the wild-type (wt)
profile and patient 13 respective variations. Five healthy control individuals were used has a reference curve. f) Chromatogram analysis resulting
from sequencing exon 22 of the MYH7 gene in patient 13. g) Polyphen analysis of p.Ala862Val genetic variation http://genetics.bwh.harvard.edu/
pph2/. h) Conservation across species of codon 862 of the b-myosin protein (source: http://www.uniprot.org/). The box shows the amino acid
changed by the MYH7 c.2585 C > T mutation. [BOVIN - Bos Taurus; HUMAN - Homo sapiens; MOUSE - Mus musculus; RAT - Rattus norvegicus; PIG
- Sus scrofa].
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Page 9 of 13http://genetics.bwh.harvard.edu/pph2/ could suggest that
most of these novel missense variants are most likely
disease causing (Figures 2d, 3d and 4d and results not
shown). Two novel mutations in MYH7 gene, c.613 A >
T (p.Ser205Cys) and c.2585 C > T (p.Ala862Val) in
exons 7 and 22, respectively, despite being classified by
PolyPhen software as benign, the protein alignments
(source: http://www.uniprot.org/) show that the amino
acids changed by the mutations are conserved across
species (Homo sapiens; Mus musculus; Rattus norvegicus;
Bos Taurus; Danio rerio) (data not shown and Figure 1g
and 1h, respectively).
Prevalence and spectrum of mutations in the Portuguese
population: Correlation with clinical data
Our HRM strategy allowed us to found 36 patients with
mutations in MYH7 (45%), 24 patients with MYBPC3
mutations (30%), 9 patients with TNNI3 mutations
(11.25%), 6 patients with TNNT2 mutations (7.5%), 5
patients with CSRP3 mutations (6.25%), 1 patient with a
MYH6 mutation (1.25%) and 1 patient with a MYL2
mutation (1.25%) (Table 3). As previously described by
others, in the cohort of HCM patients analyzed in this
work, MYH7 and MYBPC3 mutations accounts for 75%
of the HCM cases [this work and [1,7,8]]. Also, this
mutation distribution allow us to verify that in our stu-
died HCM cohort there are no prevalent mutations as
described in the Netherlands [20] but a marked genetic
heterogeneity as most HCM patients have a unique
pathogenic mutation such as reported before in the US
[1,22]. As reported above, in our cohort we were able to
detect 22 novel mutations in MYBPC3, MYH7, TNNT2,
TNNI3, MYH6, MYL2 and CSRP3 genes (Table 3 and
Figures 1- 4). Most of these are missense mutations
(25%), one is an indel mutation, another a 5’ UTR
Figure 2 a) Melting curves of exon 2 of the MYH6 gene
(NM_002471). b) Difference plot of the melting curves. The arrows
in both figures indicate the wild-type (wt) profile and the patient
respective variation. Seven healthy control individuals were used has
a reference curve. c) Chromatogram analysis resulting from
sequencing exon 2 of the MYH6 gene in patient 37. d) Polyphen
analysis of p.Gly56Arg genetic variation http://genetics.bwh.harvard.
edu/pph2/. e) Conservation across species of codon 56 of the a-
myosin light chain protein (source: http://www.uniprot.org/). The
box shows the amino acid changed by the MYH6 c.220 G > A
mutation. [HUMAN - Homo sapiens; MOUSE - Mus musculus; RAT -
Rattus norvegicus; DANRE - Danio rerio].
Figure 3 a) Melting curves of exon 14 of the TNNT2 gene
(NM_000364). b) Difference plot of the melting curves. The arrows
in both figures indicate the wild-type (wt) profile and the patient
respective variation. Eight healthy control individuals were used has
a reference curve. c) Chromatogram analysis resulting from
sequencing exon 14 of the TNNT2 gene in patient 22. d) Polyphen
analysis of p.Lys241Met genetic variation http://genetics.bwh.
harvard.edu/pph2/. e) Conservation across species of codon 241 of
the Troponin T protein (source: http://www.uniprot.org/). The box
shows the amino acid changed by the TNNT2 c.722A > T mutation.
[HUMAN - Homo sapiens; MOUSE - Mus musculus; RAT - Rattus
norvegicus; BOVIN - Bos Taurus; DANRE - Danio rerio].
Figure 4 a) Melting curves of exon 3 of the MYL2 gene
(NM_000432). b) Difference plot of the melting curves. The arrows
in both figures indicate the wild-type (wt) profile and the patient
respective variation. Eight healthy control individuals were used has
a reference curve. c) Chromatogram analysis resulting from
sequencing exon 3 of the MYL2 gene in patient 35. d) Polyphen
analysis of p.Ile44Met genetic variation http://genetics.bwh.harvard.
edu/pph2/. e) Conservation across species of codon 44 of the
regulatory myosin light chain protein (source: http://www.uniprot.
org/). The box shows the amino acid changed by the MYL2 c.132 T
> G mutation. [HUMAN - Homo sapiens; MOUSE - Mus musculus;
RAT - Rattus norvegicus; BOVIN - Bos Taurus; RABIT - Oryctolagus
cunic].
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Page 10 of 13mutation and the two other mutations probably affect
splicing of corresponding introns. These novel muta-
tions affect amino acids that are highly conserved
among species (Table 3 Figures 1-4 and data not
shown) and they were not found in 200 chromosomes
from normal Caucasian individuals (data not shown)
indicating that they can be the cause of HCM in these
patients. Nevertheless, segregation studies are currently
being performed in their families.
Moreover, our strategy allowed us to identify muta-
t i o n si nt h r e eg e n e s( MYH6, MYL2 and CSRP3),n o t
usually analysed by current HCM-genetic diagnostic
strategy, in seven HCM patients (8.75%). This fact
prompts the importance of a complete gene scanning
analysis against the current genetic evaluation (through
AS) of the 4 most common HCM-genes (Table 1).
There are several genetic causes for LVH meaning
that a differential diagnosis by means of an accurate cor-
relation between clinical data genetic profile could be
important considering individualized treatment options
and accurate prognosis. All individuals with double
mutations (3, 7, 10, 11, 13, 21, 27, 33, 35, 37, 39, 43, 45
and 47) shared a non obstructive septal hypertrophy and
had familial history of HCM (Tables 2 and 3). In this
regard familial history can be considered as an impor-
tant parameter to be considered, as individuals 12 and
22 (with three and four mutations, respectively) have
familial history of HCM (Tables 2 and 3). Also, muta-
tions in MYH7 and MYBPC3 genes were involved in all
this cases (Table 3). This type of mutational profile cor-
relates to clinical data previously described for HCM-
causing mutations in MYBPC3 genes [4]. The presence
of SNPs in addition to mutations should be considered
regarding HCM severity. An example is related to indi-
vidual 1, which deceased, and has the same mutation as
individuals 25 and 26, but with an additional SNP
(Tables 2 and 3).
As mentioned before, in order to confirm the co-seg-
regation of the novel mutations with the disease, segre-
gation studies are currently being performed whenever
relatives are available for genetic studies and after
genetic counseling. In this regard, the mutation
c.1945insT1941-1946delCCTGGA, p.Pro647fs was also
present in the son of patient 16 (also with clinical diag-
nostic of HCM) (Figure 4 and 4 results not shown).
Nevertheless, patient 16 has a more severe HCM clinical
profile (the implantation of a cardiac defibrillator (CDI)
was necessary), so most probably individual 16 has
another mutation in other DNA region/gene, not ana-
lysed under current work (Table 2). Interestingly,
patients 44, 45 and 46 co-segregate MYH7 and TNNT2
mutations within their families (not related), being those
intronic variants novel (Table 3 and results not shown).
Patient 46 also co-segregates a TNNI3 mutation with his
father and patient 45 has a mutation in TNNI3 gene,
not present in both her parents (Table 3 and results not
shown). This fact is coincident with HCM genetic pro-
file being characteristic of each family and once again
highlights the importance of familial study.
In order to access some more considerations between
HCM phenotype and the genetic results presented in
this work for our cohort of HCM patients, we observe
that apical hypertrophy is mostly related with MYBPC3
and MYH7 mutations, namely intronic variants, mis-
sense and deletions (Tables 2 and 3). Curiously, two
patients (69 and 73) with apical hypertrophy presented
only a TNNT2 genetic alteration (SNP and intronic,
respectively), indicating that another DNA region, not
yet found, may also be involved in this type of cardiac
hypertrophy (Tables 2 and 3). Regarding septal hyper-
trophy MYH7, MYBPC3, MYH6, TNNT2 and CSRP3
genes are affected and curiously only one mutation is
shared between apical and septal hypertrophy (Tables 2
and 3).
Within our analyzed cohort we had 39 sporadic cases
which constitute 48.75% of the HCM cases, being the
rest (51.25%) familial cases (Table 2). From the eight
patients with no identified HCM-associated mutations
Figure 5 a) Melting curves of exon 14 of the TNNT2 gene
(NM_000364). b) Difference plot of the melting curves. The arrows
in both figures indicate the wild-type (wt) profile and the patients
respective variations. Nine healthy control individuals were used has
a reference curve. c) Chromatogram analysis resulting from
sequencing exon 14 of the TNNT2 gene in patient 67. d) Polyphen
analysis of p.Lys260Arg genetic variation http://genetics.bwh.harvard.
edu/pph2/. e) Conservation across species of codon 260 of the
cardiac Troponic T protein (source: http://www.uniprot.org/). The
box shows the amino acid changed by the TNNT2 c.778A > G
mutation. [HUMAN - Homo sapiens; MOUSE - Mus musculus; RAT -
Rattus norvegicus; CANFA - Canis familiaris; RABIT - Oryctolagus
cunic]. f) Melting curves of the population study of exon 14 of the
TNNT2 gene (NM_000364). g) Difference plot of the melting curves.
The arrows in both figures indicate the wild-type (wt) profile and
the c.778A > G (p.Lys260Arg) variation on two chromosomes of
control individuals. 100 healthy control individuals (200
chromosomes) were used has a reference curve.
Santos et al. BMC Medical Genetics 2012, 13:17
http://www.biomedcentral.com/1471-2350/13/17
Page 11 of 13six of them (patients 19, 36, 40, 63, 64 and 65) were
sporadic cases, being this observation in agreement
with previous results [1,7,8]. Nevertheless, all the
above considerations regarding genotype and pheno-
type should be validated using a major sampling of
HCM patients with all the necessary clinical character-
ization/data. Another limitation of our work concerns
with the establishment of the effect of novel DNA
alterations as the cause of HCM. In order to determine
the phenotypic effects of DNA alterations it becomes
necessary to perform functional studies, including
assessment of protein interaction. In this perspective
we initiated functional studies namely of the 5’UTR
mutation, the splicing mutations and the indel muta-
tion that are being evaluated by means of two-hybrid
system in cardiomyocyte cell lines.
Conclusions
In our work we intended to improve gene-based diag-
nostic tools by using a recent high throughput genotyp-
ing technology. The rapid, low-cost, and highly efficient
HRM strategy fulfills all the conditions required for the
systematic detection of genomic variants in the 28
HCM-associated genes, being able to detect DNA var-
iants in 90% of the analyzed HCM patients with 20% of
the patients showing more than one mutation (double
or compound heterozygosity). We were also able to con-
firm a marked genetic heterogeneity regarding HCM in
o u rc o h o r to fp a t i e n t sa sm o s tp a t i e n t sh a v ea“private”
pathogenic mutation. As far as we know this is the first
study applying HRM technology for scanning 28 HCM-
associated genes in a large cohort of Portuguese Cauca-
sian HCM patients. The elucidation of the molecular
basis of HCM cases will provide new insights into geno-
type/phenotype relationships and will allow a better
knowledge of the HCM physiopathology. However, it
should be noted that the difficulty in obtaining the clini-
cal data for all our HCM patients, can be considered as
a major limitation in order to obtain accurate genotype
- phenotype correlations.
Additional material
Additional file 1: Table 1Genomic regions covered in HRM analysis.
Primer sequences and PCR conditions for HCM-associated genes
mutation scanning by HRM are described.
Additional file 2: Figure 1a) Melting curves of exon 9 of the MYH7
gene (NM_000257). b) Difference plot of the melting curves. The arrows
in both figures indicate the wild-type (wt) profile and patient 18
respective variations. Three healthy control individuals were used has a
reference curve. The altered profile was also obtained for patients 27 and
38.c) Melting curves of exon 11 of the MYH7 gene (NM_000257). d)
Difference plot of the melting curves. The arrows in both figures indicate
the wild-type (wt) profile and patient 39 respective variations. Three
healthy control individuals were used has a reference curve. e) Melting
curves of exon 14 of the MYH7 gene (NM_000257). f) Difference plot of
the melting curves. The arrows in both figures indicate the wild-type (wt)
profile and patient 43 respective variations. Five healthy control
individuals were used has a reference curve. g) Melting curves of exon
19 of the MYH7 gene (NM_000257). h) Difference plot of the melting
curves. The arrows in both figures indicate the wild-type (wt) profile and
patient 39 respective variations. Four healthy control individuals were
used has a reference curve.
Additional file 3: Figure 2a) Melting curves of exon 23(1) of the
MYBPC3 gene (NM_000256). b) Difference plot of the melting curves.
The arrows in both figures indicate the wild-type (wt) profile and patient
22 respective variations. Two healthy control individuals were used has a
reference curve; c) Melting curves of exon 25 of the MYBPC3 gene
(NM_000256). d) Difference plot of the melting curves. The arrows in
both figures indicate the wild-type (wt) profile and patient 7 respective
variations. Five healthy control individuals were used has a reference
curve. The altered profile was also obtained for patients 25 and 26; e)
Melting curves of exon 30 of the MYBPC3 gene (NM_000256). f)
Difference plot of the melting curves. The arrows in both figures indicate
the wild-type (wt) profile and patient 1 respective variations. Four healthy
control individuals were used has a reference curve.
Additional file 4: Figure 3a) Melting curves of exon 15 of the TNNT2
gene (NM_000364). b) Difference plot of the melting curves. The arrows
in both figures indicate the wild-type (wt) profile and patient 71
respective variations. Nine healthy control individuals were used has a
reference curve. c) Melting curves of exon 7 of the TNNI3 gene
(NM_000363). d) Difference plot of the melting curves. The arrows in
both figures indicate the wild-type (wt) profile and patients respective
variations (green curve for patient 74 and red curves for patients 75 and
76). Patient 15 also had a similar red profile. Four healthy control
individuals were used has a reference curve. e) Melting curves of exon 3
of the CSRP3 gene (NM_003476). f) Difference plot of the melting curves.
The arrows in both figures indicate the wild-type profile and patients 22
and 78 respective variations. Ten healthy control individuals were used
has a reference curve. The altered profile was also obtained for patient
79.
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